These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 30391211

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
    Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, Hong S, Jung HS, Oh E, Song JY, Lee MS, Kim M, Jung K, Kim J, Shin YK, Choi YL, Kim HR.
    J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study.
    Yu Y, Zhang Q, Zhang J, Lu S.
    J Cancer Res Ther; 2019 Aug; 15(4):909-913. PubMed ID: 31436251
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
    Shi M, Ma J, Feng M, Liang L, Chen H, Wang T, Xie Z.
    Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998
    [Abstract] [Full Text] [Related]

  • 12. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM.
    J Clin Oncol; 2016 Mar 01; 34(7):721-30. PubMed ID: 26729443
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.
    Clin Cancer Res; 2019 Feb 15; 25(4):1248-1260. PubMed ID: 30352902
    [Abstract] [Full Text] [Related]

  • 15. MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.
    Poirot B, Doucet L, Benhenda S, Champ J, Meignin V, Lehmann-Che J.
    J Thorac Oncol; 2017 Oct 15; 12(10):1582-1587. PubMed ID: 28779874
    [Abstract] [Full Text] [Related]

  • 16. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug 15; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 17. Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective.
    Subramanian J, Tawfik O.
    Expert Rev Anticancer Ther; 2021 Aug 15; 21(8):877-886. PubMed ID: 33957836
    [Abstract] [Full Text] [Related]

  • 18. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG.
    J Thorac Oncol; 2019 Sep 15; 14(9):1666-1671. PubMed ID: 31228623
    [Abstract] [Full Text] [Related]

  • 19. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.
    Clin Cancer Res; 2020 Jan 15; 26(2):439-449. PubMed ID: 31548343
    [Abstract] [Full Text] [Related]

  • 20. MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
    Heist RS, Shim HS, Gingipally S, Mino-Kenudson M, Le L, Gainor JF, Zheng Z, Aryee M, Xia J, Jia P, Jin H, Zhao Z, Pao W, Engelman JA, Iafrate AJ.
    Oncologist; 2016 Apr 15; 21(4):481-6. PubMed ID: 27022036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.